ecrin-mdr-crcClinical2023IPD Sharing (as of October 2023): NoPancreatic cancerColorectal cancerAdvanced Solid TumorNeoplasmsColorectal CancerAdvanced Solid TumorPancreatic CancerNeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/114258China11NKG2AUrothelial carcinomaHumanized monoclonal antibodyECRIN MDRNot yet recruitingfalseA Study of HY-0102 in Patients With Advanced Solid TumorsThis is a phase 1 open label multicenter study to evaluate the maximum tolerance, safety, tolerance and PK of HY-0102 administered intravenously (IV) once every two weeks in patients with advanced solid tumors, so as to confirm the recommended phase 2 dose of HY-0102 and obtain the preliminary efficacy information of patients with advanced solid tumors.2023-11-15114258NCT06094777